Financial Performance - Q2 2022 net revenues increased by 6% to $267 million, with a 9% increase on a constant currency basis[24] - Adjusted EBITDA for Q2 2022 increased by 1% to $136 million[24] - Adjusted EPS for Q2 2022 increased from $0.26 to $0.27[24] - YTD 2022 revenue increased 8% to $503 million compared to $464 million in 2021[34] - YTD 2022 Adjusted EBITDA increased 5% to $251 million compared to $240 million in 2021[35] - YTD 2022 Adjusted EPS increased 11% from $0.44 to $0.49[37, 39] Segment Performance - Sterigenics Q2 2022 revenue increased by 9% and segment income increased by 7%[41] - Nordion Q2 2022 revenue increased by 3%, but segment income decreased by 4%[47] - Nelson Labs Q2 2022 revenue increased by 1%, but segment income decreased by 12%[52] Investments and Capital Deployment - Capital expenditures increased by approximately 60% compared to the first half of 2021[26, 59] - Net leverage is at 3.4x with continued strong liquidity[26] Market Outlook - The company estimates a total addressable market (TAM) of approximately $33 billion[11, 18] - The company estimates a serviceable addressable market (SAM) of approximately $11 billion[18] - Full-year 2022 revenue is expected to be between $1 billion and $1022 million, representing a 7% to 10% year-over-year increase[63] - Full-year 2022 Adjusted EBITDA is expected to be between $515 million and $525 million, representing a 7% to 9% year-over-year increase[63]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...

Fourth-Quarter and Full-Year 2021 Earnings Results March 1, 2022 Forward Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This presentation contains forward-looking statements that reflect management's expectations about future events and the Compan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I. ...

Sotera Health Company (NASDAQ:SHC) Q4 2021 Earnings Conference Call March 1, 2022 9:00 AM ET Company Participants Michael Petras - Chairman and CEO Scott Leffler - CFO Conference Call Participants Matt Miksic - Credit Suisse Sean Dodge - RBC Capital Markets Matthew Mishan - KeyBanc Luke Sergott - Barclays Tycho Peterson - JPMorgan Dave Windley - Jefferies Amit Hazan - Goldman Sachs Luke Sergott - Barclays Operator Good morning. This is Norma, and welcome to Sotera Health Fourth Quarter 2021 Results Call. Yo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 Indicate by check mark whether the registrant has submitted electronically every Interactive Data Fi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | | --- | --- | --- | | (State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) | | 9100 South Hills Blvd, Suite 300 | | | | Broadview Heights, Ohio | | 44147 | | (Address of principal executive offices) | | (Zip Code) | | Regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 47-3531161 (State or other jurisdiction of incorporation ...